Home Newsfeeds Purple Biotech Q3 EPS $(0.27)

Purple Biotech Q3 EPS $(0.27)

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.

byBill Haddad

November 8, 2022

1 minute read

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.

Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation For The Treatment Of High-Risk Non-Muscle-Invasive Bladder Cancer

By Benzinga Newsdesk

December 4, 5:33 PM

Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 StudyRARITAN, N.J., Dec. 4, 2023 /PRNewswire/ -- Johnson & Johnson announced today that the U.S.

JNJ

Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Mo…

By Benzinga Newsdesk

May 21, 8:38 AM

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for

BDRX